Veeva Systems (VEEV)

Vertical SaaS for life sciences (pharma) — industry-specific CRM + clinical/regulatory/quality software

AI exposure 8% — derived from reported segment revenue, not asserted.

Where it sits

Software Stack → Enterprise & Business Software · figures rebased to Q2 FY2027, reported 2026-08-27

Pure vertical enterprise SaaS (CRM, content, clinical/regulatory data mgmt). Competes with Salesforce (CRM) — NOT with medtech/device makers (GEHC/ISRG). Healthcare/life-sciences is its END-MARKET, shown via value chain, not its product category. Primary B5 Enterprise & Business Software.

Reported segments

Subscription services — 82.6% of revenue
Professional services & other — 17.4% of revenue

Veeva ($928.0M Q2 FY2027, +17.6% YoY). ONE reportable segment — industry cloud solutions for life sciences. The split below is the revenue disaggregation Veeva discloses rather than an ASC 280 segment split: subscription 82.6% ($766.8M) and professional services 17.4% ($161.2M). Within subscription, Veeva reports two product areas, and they crossed this quarter — R&D and Quality Solutions $419.4M (45.2% of total, +19.3% YoY) now runs ahead of Commercial Solutions $347.4M (37.4%, +13.0%). The clinical and regulatory side is the growth engine, not the sales tooling the company was founded on.

How the 8% is built

Subscription services — 82.6% of revenue × 8% AI-driven (disclosed). Life-sciences workflow software bought for regulatory compliance and clinical operations; AI features are attached to Vault rather than being the reason it is purchased
Professional services & other — 17.4% of revenue × 10% AI-driven (disclosed). Implementation and data services, including the data-preparation work that AI-assisted clinical workflows depend on

Investment read

Moat. A near-captive life-sciences vertical: Vault clinical, regulatory and quality systems are GxP-validated inside customers' own compliance frameworks, so replacement is a revalidation project rather than a procurement decision. The commercial half is mid-migration onto Veeva's own Vault CRM — 150+ customers live (from zero in 2024), Merck KGaA and Teva committed globally in May 2026 — and December 2029 legacy end-of-support makes the remaining base a captive migration wave.

Bottleneck / pricing power. Strong pricing power — 45% non-GAAP operating margin and ~87% subscription gross margin in Q1 FY2027, with R&D/Quality subscriptions growing 19% YoY. Two real constraints: growth is decelerating (FY2027 guided to ~13% from 16%), and professional services grew 23% YoY, faster than subscriptions, which management has flagged as a margin headwind.

Role in the AI stack. The life-sciences vertical-cloud layer (AI applier).

Connected companies

Salesforce (CRM) — VEEV competes with: Life-sciences CRM — Veeva Vault CRM vs Salesforce Life Sciences Cloud, now direct rivals after the non-compete expired (2025)
Oracle (ORCL) — VEEV competes with: life-sciences clinical/regulatory software — Veeva Vault vs Oracle Health Sciences (Oracle Clinical/Siebel CTMS/Argus)

Others in Enterprise & Business Software

All 174 companies · What moved this quarter · How the map is built